We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Blood Test Increases Accuracy in Prenatal Testing

By LabMedica International staff writers
Posted on 22 Nov 2015
Print article
Image: The Qubit Fluorometer accurately detects and quantifies very low concentrations of DNA, RNA, and protein (Photo courtesy of Great Lakes Genomics Center).
Image: The Qubit Fluorometer accurately detects and quantifies very low concentrations of DNA, RNA, and protein (Photo courtesy of Great Lakes Genomics Center).
A simple, accurate and low risk blood test can detect fetal blood group, sex, and genetic conditions in unborn babies and the DNA test is inexpensive and is noninvasive, as opposed to the traditional amniocentesis test that involves a needle and carries a minor risk of miscarriage.

Laboratory methods have been evaluated for noninvasive genotyping of fetal RHD (Rh blood group, D antigen) that can prevent the unnecessary administration of prophylactic anti-D to women carrying RHD-negative fetuses. The test developed can be carried out on mothers at risk of X-linked genetic recessive diseases including hemophilia and Duchenne muscular dystrophy and mothers at risk of hemolytic disease of the new-born.

Scientists at the University of Plymouth (UK) recruited RHD-negative pregnant women (28 to 30 weeks' gestation), all of whom met inclusion criteria, from November 2013 to September 2014. Twenty-two maternal peripheral blood samples were collected in Ethylenediaminetetraacetic acid (EDTA) tubes and centrifuged at 1,600×g for 10 minutes at room temperature (samples 1–22). The plasma was carefully removed and transferred to a 15-mL tube. The plasma was then re-centrifuged at 16,000×g for 10 minutes.

Twenty-four maternal blood samples collected in Streck Cell-Free DNA blood collection tubes (Streck BCTs; La Vista, NE, USA) were centrifuged at 1,600×g for 15 minutes at room temperature (samples 23–46). Plasma was carefully removed, transferred to a 50-mL tube, and re-centrifuged at 2,500×g for 10 minutes. DNA was extracted from two 1-mL aliquots of plasma and quantified samples on the Qubit 2.0 Fluorometer (Thermo Fisher; Waltham, MA, USA). Using Y-specific and RHD-specific targets, the team investigated variation in the cell-free fetal DNA (cffDNA) fraction and determined the sensitivity achieved for optimal and suboptimal samples with a novel Droplet Digital polymerase chain reaction (ddPCR, Bio-Rad Laboratories; Hercules CA, USA) platform compared with real-time quantitative PCR (qPCR).

The cffDNA fraction was significantly larger for samples collected in Streck BCTs compared with samples collected in EDTA tubes. In samples expressing optimal cffDNA fractions greater than 4%, both qPCR and ddPCR showed 100% sensitivity for the testis-specific protein, Y-linked 1(TSPY1) and RHD exon 7 (RHD7) assays. Although ddPCR also had 100% sensitivity for RHD exon 5 (RHD5), qPCR had reduced sensitivity (83%) for this target. For samples expressing suboptimal cffDNA fractions, less than 2%, ddPCR achieved 100% sensitivity for all assays, whereas qPCR achieved 100% sensitivity only for the TSPY1 multicopy target assay.

Neil D. Avent, PhD, a professor and lead author of the study, said, “Although fetal blood grouping and sexing using maternal blood has been done for over a decade, this study proves a much more accurate and sensitive method of detecting fetal DNA. This offers great opportunities to detect other conditions using this technique, but is much cheaper than current noninvasive methods. The end is now in sight for the invasive techniques of amniocentesis and chorionic villus sampling.” The study was published in the November 2015 issue of the journal Clinical Chemistry.

Related Links:

University of Plymouth 
Streck
Thermo Fisher



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.